JAMP MIDODRINE TABLET

Država: Kanada

Jezik: engleski

Izvor: Health Canada

Aktivni sastojci:

MIDODRINE HYDROCHLORIDE

Dostupno od:

JAMP PHARMA CORPORATION

ATC koda:

C01CA17

INN (International ime):

MIDODRINE

Doziranje:

2.5MG

Farmaceutski oblik:

TABLET

Sastav:

MIDODRINE HYDROCHLORIDE 2.5MG

Administracija rute:

ORAL

Jedinice u paketu:

15G/50G

Tip recepta:

Prescription

Područje terapije:

ALPHA-ADRENERGIC AGONISTS

Proizvod sažetak:

Active ingredient group (AIG) number: 0123066001; AHFS:

Status autorizacije:

APPROVED

Datum autorizacije:

2021-07-08

Svojstava lijeka

Page 1 of 22
PRODUCT MONOGRAPH
Pr
JAMP MIDODRINE
Midodrine Hydrochloride Tablets USP
2.5 mg and 5 mg of midodrine hydrochloride
Vasopressor
JAMP PHARMA CORPORATION
1310 rue Nobel
Boucherville, Qu
é
bec
J4B 5H3
DATE OF PREPARATION:
June 30, 2021
CONTROL NO.: 235448
Page 2 of 22
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................... 4
SUMMARY PRODUCT INFORMATION
.........................................................................
4
INDICATIONS AND CLINICAL USE
..............................................................................
4
CONTRAINDICATIONS
..................................................................................................
5
WARNINGS AND PRECAUTIONS
..................................................................................
5
ADVERSE
REACTIONS...................................................................................................
7
DRUG INTERACTIONS
...................................................................................................
9
DOSAGE AND ADMINISTRATION
...............................................................................10
OVERDOSAGE
...............................................................................................................11
ACTION AND CLINICAL PHARMACOLOGY
...............................................................11
STORAGE AND STABILITY
..........................................................................................12
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................13
PART II: SCIENTIFIC
INFORMATION.........................................................................
14
PHARMACEUTICAL INFORMATION
...........................................................................14
CLINICAL TRIALS
.........................................................................................................16
DETAILED PHARMACOLOGY
............................................................................